SI earnings analysis
What we found in SI's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Shoulder Innovations reported strong Q1 2026 results, with revenue reaching $16.7 million, up 64.9% year-over-year, significantly exceeding analyst expectations of $14.35 million. Despite an EPS loss of $0.41, which was better than the anticipated loss of $0.44, the company raised its full-year revenue guidance to between $65 million and $68 million, reflecting confidence in future growth supported by increased sales and operational efficiencies.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Strong Revenue Growth
- Revenue jumped 64.9% to $16.7 million from $10.1 million in Q1 2025.
- EPS Better Than Expectations
- Actual EPS loss was $0.41 versus an estimated loss of $0.44, outperforming estimates.
- Increased Revenue Guidance
- Management raised FY2026 revenue guidance to $65M-$68M from $62M-$65M, indicating strong growth expectations.
- Improved Gross Margin
- Gross margin improved to 77.7% in Q1 2026 from 76.9% in Q1 2025.
- Higher Implant Sales
- Sales of implant systems increased significantly, contributing to overall revenue growth.
- Reduced Interest Expense
- Interest expense net improved to income of $436K, from prior expense of $367K, due to increased interest on marketable securities.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Higher Operating Expenses
- Total operating expenses surged 81.7% to $21.96 million compared to $12.09 million in Q1 2025.
- Continued Net Losses
- Net loss widened to $8.38 million from $4.66 million a year ago, raising concerns about profitability.
- Dependence on Third-Party Manufacturers
- Outsourcing production may expose the company to supply chain risks and pricing pressures.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.41
- Gross margin
- 77.7%
What they said about what is next.
Revenue guidance raised from $62M-$65M to $65M-$68M for FY2026.
The filing reads better than the one before it.
What came before.
- 10-K · March 10, 2026
- Shoulder Innovations positions itself as a specialist, commercial-stage medtech company focused exclusively on shoulder arthroplasty with a purpose-built ecosystem (InSet implants, ProVoyance planning, two‑tray…
- 10-Q · November 12, 2025
- Shoulder Innovations reported Q3 revenue of $11,756,000 (three months ended September 30, 2025), up 57.7% year-over-year from $7,454,000, while gross margin remained high at 76.2%. Operating loss widened to $7,641,000…
- 10-Q · September 9, 2025
- Shoulder Innovations reported revenue of $11.013 million for the quarter ended June 30, 2025, up from $8.260 million in the prior-year quarter, with gross profit of $8.393 million (≈76.2% gross margin). Despite top-line…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing SI makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever